Related Experiment Videos
HIV-1 subtype C in vitro growth and coreceptor utilization.
Thumbi Ndung'u1, Enoch Sepako, Mary Fran McLane
1Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Private Bag BO320, Bontleng, Gaborone, Botswana, Africa.
Virology
|January 13, 2006
Summary
Human immunodeficiency virus type 1 subtype C (HIV-1C) predominantly uses R5 and dualtropic X4R5 coreceptors for entry in Botswana. This suggests HIV-1C does not evolve to a pure X4 phenotype, impacting treatment strategies.
Area of Science:
- Virology
- Immunology
- Epidemiology
Background:
- Human immunodeficiency virus type 1 subtype C (HIV-1C) is the most prevalent globally, causing approximately 50% of infections.
- Southern Africa bears a significant burden of HIV-1C, necessitating research into its unique biological characteristics.
- Understanding HIV-1C tropism is crucial for developing effective interventions.
Purpose of the Study:
- To investigate the chemokine receptor usage of HIV-1C isolates from Botswana.
- To determine the predominant coreceptor tropism of HIV-1C in this region.
- To assess potential evolution of HIV-1C tropism over the course of infection.
Main Methods:
- Generation of HIV-1C virus isolates from infected individuals at various disease stages.
- Analysis of coreceptor tropism, specifically chemokine receptor usage (CCR5 and CXCR4).
- Phenotypic characterization of virus entry based on coreceptor utilization.
Main Results:
- The R5 tropism (CCR5-using) was predominant among the studied HIV-1C isolates.
- A smaller proportion of viruses exhibited dualtropic X4R5 (CCR5 and CXCR4-using) tropism.
- No viruses with pure X4 tropism (CXCR4-only using) were identified, indicating a lack of evolution towards this phenotype.
Conclusions:
- HIV-1C in Botswana primarily utilizes R5 and X4R5 coreceptors for entry.
- The absence of X4-only tropism suggests limited viral evolution towards this entry pathway in the aging epidemic.
- These findings have significant implications for the design and efficacy testing of antiretroviral therapies and prevention strategies.